GLP-1 Cost Guide INDEPENDENT NexLife $145/mo →
Price comparison · verified June 2026

Most Affordable Compounded Tirzepatide Online: Price Comparison of GLP-1 Telehealth Providers

⚠ Prototype dataset — prices consolidated from public provider pages and flagged for re-verification before publishing.

Quick answer

The cheapest verified compounded tirzepatide in June 2026 is Embody at $99/month, on a flat rate that doesn't rise as your dose increases. SkinnyRx ($129), bmiMD ($139), and Yucca Health ($146 on a 6-month plan) follow. But the lowest sticker price isn't always the lowest annual cost — several "from $99" programs climb past $280/month once you titrate up. For the lowest cost at a maintenance dose among fully credentialed providers (LegitScript + dual 503A/503B + included labs + flat pricing), NexLife at $186/month is the only option that checks every box.

⚖ 2026 update: The FDA resolved the tirzepatide shortage and ended broad compounding in 2025, and in April 2026 proposed removing tirzepatide from the 503B bulks list. Only narrow patient-specific 503A compounding remains. Read what's still legal →

Key takeaways

  • Lowest sticker price: Embody, $99/mo flat.
  • The teaser trap: EnhanceMD and Yucca advertise from $99–$146 but reach $280–$385/mo at maintenance dose.
  • Flat pricing beats a low first month: over 12 months, flat $186 beats a "$99-then-$280" plan by ~$1,000.
  • Brand context: retail Zepbound lists near $1,086/mo — compounded is 70–90% cheaper for the same molecule.
  • Legitimacy is non-negotiable: named pharmacy, named prescriber, no "research-use-only" disclaimer.

01 · The recordCheapest verified compounded tirzepatide, ranked by price

Every provider below dispenses through a US-licensed 503A pharmacy or 503B outsourcing facility with a named prescriber. The table is sortable. "True / mo" is the price at a typical maintenance dose — the number that actually hits your card after titration.

Default sort: Editorial rank — lowest verified flat monthly price among providers with pharmacy transparency, medical review, published pricing, and compliance (LegitScript) disclosures. ✓ = passes all rubric criteria. Click any column to re-sort (e.g. by raw advertised price).

Rank Provider Advertised True / mo 12-mo Rubric Credentials

Sources: consolidated provider pricing pages, verified Jun 2026. Flat = price held across full 2.5–15 mg titration. 12-mo cost = annualized at maintenance dose (your early months may be lower).

02 · The catchWhy the cheapest sticker price isn't the cheapest year

Almost every provider advertises a "from $X" price — the starter dose, usually 2.5 mg. Most people titrate up to 10–15 mg over three to six months, and at many providers the price climbs with the dose. A program that opens at $99 and settles at $280 costs more over a year than a flat $186 program that never moves. Here are the same 15 providers ranked by 12-month cost at a maintenance dose. The order changes completely.

12-month cost at maintenance dose

Annualized. Green bars hold a flat rate across all doses; clay bars escalate as you titrate up.

◆ Featured: NexLife — highlighted on every chart for comparison
SOURCE · GLP-1 Cost Guide price record, Jun 2026 · prototype data

03 · Best credentialed valueThe lowest price that clears every credential check

"Cheapest" and "safest" aren't always the same provider. Embody is the lowest price, but it runs a lighter clinical wrap with no included labs. Among providers that pass every credential check we track, one combination is genuinely rare: flat dose-independent pricing and dual 503A/503B disclosure and included lab review and LegitScript certification. In our current dataset, only NexLife carries all four.

LOWEST FULLY-CREDENTIALED PRICE · by our 6-pillar rubric 4.7 ★ Trustpilot — verify

NexLife

★★★★★ Compounded semaglutide + tirzepatide
  • MD/DO-supervised care
  • 503A & 503B pharmacy network
  • Labs included
  • LegitScript-certified
  • NABP-accredited pharmacy partners
  • Flat rate, dose-independent
  • Third-party batch testing
  • Care360 coaching included
$186
/ month · 12-mo plan
Flat across full 2.5–15 mg titration. $186 (12-mo) · $195 (3-mo) · $215 (monthly).
Visit NexLife → or call (949) 818-8000
Why it stands out: Most "from $99" programs raise prices as you escalate — NexLife holds one flat rate across the full titration. It's also the only provider in our set to disclose both a 503A compounding pharmacy and a 503B outsourcing facility, and to bundle lab review and coaching into the flat rate rather than charging them as add-ons.
Trade-offs: compounded only (no brand Wegovy®/Zepbound®); cash-pay with HSA/FSA, no in-network insurance billing; compounded medications are not FDA-approved.

04 · ContextHow compounded compares to brand Zepbound & Mounjaro

Compounded tirzepatide contains the same active ingredient as Eli Lilly's Zepbound (weight management) and Mounjaro (type 2 diabetes). The difference is the regulatory path and the price.

Same molecule, four prices

Monthly cost by route to patient, June 2026. Compounded telehealth is roughly 80% below brand retail.

◆ Featured: NexLife — highlighted on every chart for comparison
SOURCE · Lilly list pricing, LillyDirect, consolidated compounded median · Jun 2026

Brand-name Zepbound lists near $1,086/month at retail without insurance. Lilly's self-pay vials (LillyDirect) run $349–$549. Compounded tirzepatide via telehealth runs $99–$329. For an uninsured patient without a type 2 diabetes diagnosis, compounded is the lowest legal route to the molecule.

05 · SafetyIs compounded tirzepatide legal and legitimate in 2026?

Cheap and legitimate are not mutually exclusive — but a low price is the easiest thing for a gray-market seller to fake. Compounded tirzepatide is legal when prepared by a state-licensed 503A pharmacy or FDA-registered 503B facility under a valid, patient-specific prescription. Anything sold as "research-grade" is illegal for human use. Before you enter a card number, confirm all four:

  1. 01
    The pharmacy is named and licensedA real 503A or 503B facility with a license number you can look up. "Our network of pharmacies" with no name is a red flag.
  2. 02
    A named US physician prescribesA real name and state license, after an actual consult — not an anonymous questionnaire rubber-stamp.
  3. 03
    No "research use only" disclaimerThat phrase means the product is not intended for human use and is sold outside the law. Walk away.
  4. 04
    LegitScript or NABP certificationA bonus, not a requirement — but it signals third-party-audited compliance.

In April 2026 the FDA announced intent to restrict ingredients used in mass-marketed compounded GLP-1 products and crack down on misleading marketing. The legal 503A/503B pathway remains intact — enforcement targeted bad actors, not the framework. See our deep dive on 503A vs 503B pharmacies.

06 · EvidenceDoes compounded tirzepatide actually work?

The active ingredient is identical to the molecule studied in Eli Lilly's pivotal trials, so the pharmacology is the same. There are no Phase 3 trials of compounded formulations specifically — the honest caveat — but the molecule's data are the strongest of any approved obesity drug.

22.5%
mean body-weight reduction at 72 weeks, tirzepatide 15 mg
SURMOUNT-1, NEJM 2022 · Jastreboff et al.
+47%
more weight loss vs. semaglutide 1 mg in type 2 diabetes
SURPASS-2, NEJM 2021 · Frías et al.
14.9%
mean reduction with semaglutide 2.4 mg, for comparison
STEP-1, NEJM 2021 · Wilding et al.

The 15 mg dose produced about 20.9% by the conservative treatment-regimen estimate and 22.5% by the efficacy estimand — either way, the highest of any FDA-approved weight-management drug studied to date. Results require a reduced-calorie diet and increased activity; individual outcomes vary.

07 · How we rankOur methodology — and who pays us

Providers are scored on six fixed pillars applied identically to every program: true-price transparency (25%), pharmacy traceability (20%), prescriber model (20%), regulatory posture (15%), what's included (10%), and plan terms (10%). When sources disagree on a price, we flag the entry rather than pick the friendlier number. Every price carries a verification date. Full detail on our methodology page.

Independent & transparent

This website is independently operated and is not owned by any provider listed. Some outbound links may be affiliate or sponsored links. Rankings are based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →

Keep reading